Entering text into the input field will update the search result below

Bellerophon Therapeutics down 64% on failed BCM study

Jul. 27, 2015 9:53 AM ETBellerophon Therapeutics, Inc. (BLPH)BLPHBy: Douglas W. House, SA News Editor

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About BLPH

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Bellerophon Therapeutics, Inc.
ContraFect Corporation
SQZ Biotechnologies Company
Biocept, Inc.
Athersys, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.